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Abstract: Recent discoveries may change the way that multiple sclerosis (MS) is viewed, particularly
with regard to the reasons for the untoward immune response. The fact that myelin proteins are
long-lived, and that by the time we are adults, they are extensively degraded, alters our perspective
on the reasons for the onset of autoimmunity and the origin of MS. For example, myelin basic protein
(MBP) from every human brain past the age of 20 years, is so greatly modified, that it is effectively a
different protein from the one that was laid down in childhood. Since only a subset of people with
such degraded MBP develop MS, a focus on understanding the mechanism of immune responses
to central nervous system (CNS) antigens and cerebral immune tolerance appear to be worthwhile
avenues to explore. In accord with this, it will be productive to examine why all people, whose brains
contain large quantities of a “foreign antigen”, do not develop MS. Importantly for the potential
causation of MS, MBP from MS patients breaks down differently from the MBP in aged controls.
If the novel structures formed in these MS-specific regions are particularly antigenic, it could help
explain the origin of MS. If verified, these findings could provide an avenue for the rational synthesis
of drugs to prevent and treat MS.
Keywords: proteomics; age-related; isoaspartate; posttranslational modification; protein
decomposition; myelin basic protein

1. Introduction
Despite many years of research, the initiating events that lead to multiple sclerosis (MS) remain a
mystery. Several genes have been linked to a higher likelihood of developing MS, in particular, those
of the human leukocyte antigen (HLA) system. A consistent finding is the association between MS
and DR15 and DQ6 alleles of the major histocompatibility complex. Genome-wide association studies
have uncovered over 200 other genes outside of the HLA locus that increase the probability of MS to a
small extent [1,2].
Environmental contributors, such as infections, have been difficult to link directly with the onset
of MS. The role of microbiota is becoming increasingly of interest following the discovery that microbes
can trigger chronic immune disorders to dietary antigens, e.g., celiac disease [3], in addition to affecting
the outcome of neurological diseases [4]. In a remarkable linkage between cellular and microbiological
strands, it has been shown recently that tryptophan metabolites derived from gut bacteria can enter
the CNS where they act on transcription factors present in microglia and astrocytes [5]. In this way,
the gut can modulate inflammation in the CNS and affect the outcome of experimental autoimmune
encephalomyelitis (EAE), a common animal model of MS.
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3. Long-Lived Proteins and Multiple Sclerosis
Amongst the list of long-lived proteins are the structural proteins of myelin [7,9]. Indeed, these
may not turn over at all. Evidence for myelin proteins being long-lived comes from two main sources.
Firstly, stable-isotope labelling revealed little or no turnover [6]. Secondly, the degree of amino acid
racemisation of human MBP as a function of age [12] matched closely that of crystallin proteins from
the lens that are well-known not to be replaced during our lifetime [7]. Once the myelin sheath is laid
down in childhood, the major proteins within it, such as myelin basic protein (MBP), may be with
us for all of our lives. Although this is, in many ways, a remarkable finding, why does this matter,
and how could this play a role in the onset of human MS?
It turns out that proteins are not stable in a biological environment. Over time they break down.
To a large degree it seems that decomposition is largely non-enzymatic and that old proteins decay
due to the intrinsic instability of certain amino acid residues. Some reactions have been known for
years. For example, aspartic acid and asparagine racemise i.e., they change from the L-form to the
D -isomer, as well as converting to a different isomeric form, isoAsp (Figure 1) [13].
Other spontaneous reactions of old proteins include crosslinking [14,15], deamidation [16],
and peptide bond cleavage [17]. It should be noted that not all modifications to long-lived proteins are
spontaneous, for example, deimination of arginine residues has been attributed to the action of protein
arginine deiminase (Figure 1).
The many novel modifications of old proteins, and their time courses as a function of age [16,18],
have been documented in the human lens, where it is well-established that proteins do not turn over [8].
It is of interest that another age-related disease, cataract, can be traced to a greater degree of protein
modification at specific sites in lens crystallins [19,20]. If these reactions are extensive, the structure
and properties of the affected long-lived proteins change dramatically. This may have significant
consequences, for example, it is possible that the body may no longer recognise the altered protein as
being “self”. If this occurs, an immune response could be mounted against the modified old protein.
These subjects have been summarised in a recent review [9].
4. Myelin Basic Protein and Age
Proteomic analysis of the human cerebellum showed that MBP is highly modified in adults [9].
The extent of posttranslational modification is large, such that every region of the protein, showed some
form of covalent alteration. In addition, these changes are quantitatively major (Figure 2). The covalent
changes included deamidation of Asn and Gln residues, isomerisation of Asp, as well as deimination of
Arg residues to citrulline. Some of these changes increased with age. Most were abundant even at age
18, which was the youngest sample available from the brain bank. That extensive MBP modification
has taken place by such a young age may at first seem surprising, however the same phenomenon has
been observed in the human lens. In the lens, the great majority of posttranslational modifications
occur by age 20 [18]. Twenty years is, after all, equivalent to incubating a life-long protein at 37 ◦ C for
more than 175,000 h!
It should be noted that the PTMs of adult myelin discussed in this article take place on MBP that
was significantly modified during development [21,22].
In accord with other long-lived proteins, one of the major changes characterised in adult human
MBP was the formation of isoAsp residues. This form of Asp is quite different from the normal
L -Asp that was present originally in the protein, and is due to the spontaneous formation of a cyclic
intermediate [13]. At each site of isoAsp formation from L-Asp (or L-Asn), the polypeptide backbone
has been extended by the insertion of a CH2 group (Figure 1). In reality, this particular modification
leads to an even greater alteration in protein structure because a common product is D-isoAsp. In this
case, the original L-amino acid site has been both extended and racemised. As well as creating novel
antigens, protein unfolding will accompany these chemical transformations.
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7. Considerations If MS Results from Age-Related Changes to MBP
There are a number of consequences that flow from the discovery that MBP is highly modified
with age and that some changes to MBP are characteristic of MS.
Firstly, if indeed human MS is an autoimmune disease provoked by an endogenously-formed
antigen, what, if any, biological processes exist to modulate the response? Can some protein
modifications be tolerated? After all, despite MBP being highly modified in all adults, only a small
fraction of people suffer disease symptoms.
To what extent does ongoing (in the adult) immune tolerance play a role in the body where there
is, in effect, a failure to respond to the formation of a major antigen that was absent at birth? Foxp3 + T
regulatory cells are likely to play an important role in this modulation. In addition, there are several
chaperone proteins present in the CNS (e.g., alpha crystallin) that can bind to modified, unfolded
proteins and in this way could cover potentially antigenic sites before they are recognised by the
immune surveillance machinery. Could this putative protective system be less effective in people who
go on to develop MS?
As with immunisation, the presence of a novel antigen alone may be insufficient to trigger a full
immune response. An adjuvant is necessary. Another immune-promoting event (e.g., an infection)
may be necessary for a complete response which ultimately leads to MS. In this regard, it is interesting
to note that bacterial and viral proteins contain unnatural amino acids such as D-isoAsp and D-isoGlu,
so molecular mimicry could play a role. It is known that there is a link between infection and MS [28]
and the presence of predisposing genes is also likely to be implicated.
T cells have long been thought to be implicated in MS pathogenesis, in particular the inflammation
associated with the condition. Recent studies have also highlighted the important contribution of B
cells. Evidence for a major role of B cells in MS is suggested by the clinical benefit derived by peripheral
B cell depletion using drugs such as rituximab, an anti-CD20 agent [29]. A possible way in which
modified MBP (and other myelin proteins) may elicit an immune response is depicted in Figure 4.
It is not yet known how normal individuals are able to maintain immunological tolerance towards
a new self-antigen (i.e., modified MBP) that is present in large amounts in the adult brain. As mentioned
above, there are some intriguing observations that suggest a role for peripheral B cell depletion in this
process. In an elegant study to determine whether B cell tolerance checkpoints are defective in MS
patients, it was discovered that most suffer from impaired peripheral B cell tolerance, resulting in the
accumulation of large numbers of autoreactive and polyreactive mature naive B cells, which express
white matter–reactive antibodies [30]. Aspects of B cell biology [31] and T cell interactions with respect
to MS have been more extensively reviewed elsewhere [32]. Interestingly, in surgical brain injury,
it has been found that immune tolerance can be induced by hepatic portal vein and intrathymic
injection of MBP [33]. Possibly, in individuals who are not affected by MS, continuous exposure to low
levels of modified MBP via the route depicted in Figure 4 may act in a similar manner to therapeutic
administration of a causative antigen as outlined by Verhagen et al. [34]. In theory, if such a mechanism
were impaired or disrupted, exposure to modified MBP may trigger MS.
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probably very little unmodified MBP left in normal adult brain. The degree of MBP modification is
simply so great. Preliminary data suggest that MBP from other brain regions is also highly modified.
Therefore, screening for antibodies to the MBP polypeptide as it was originally translated (and as it
once existed in childhood), may not be an appropriate method to assess whether MS patients have
clinically-relevant autoantibodies to adult myelin proteins.
Given the most recent proteomic data [9,26] that has uncovered brain proteins that are highly
altered in adults, a better question may be: are antibodies that recognise highly-modified MBP present
in MS patients? Antibodies may cross-react to varying degrees with the original unmodified MBP, or
possibly may not recognise it at all. Now that MS-specific sites on MBP have been characterised [9,26],
a search for antibodies to these particular sites in MS patients should be a priority. In other words,
using relevant antigens for antibody screens may be important. Unmodified (original) MBP may not
be the best choice and this factor could be one explanation for variability in the published results of
serum screening of MS patients for antibodies to MBP [44,45]. Our preliminary data indicate that
the other long-lived proteins in myelin (e.g., PLP and MOG [7]) have also been modified over time
and could potentially become new self-antigens, which have the potential to trigger autoimmunity.
The same caveats with regard to the screening for MS-relevant autoantibodies (and T cells) to these
proteins as outlined for MBP, may apply to them as well.
11. Cellular Aspects of MS
B and T cell responses to self-antigens are clearly important and mechanisms of central tolerance
for B cells have been reviewed [46]. Significant increases in the number of autoreactive B cells have
been observed in MS patients [47]. In general, it appears that B cell responses to single sites of PTM in
self-antigens are likely to be promiscuous, in the sense that the antibodies recognise both modified and
unmodified forms of the self-protein. Presumably this is because the amino acid sequences on either
side of the modification remain the same. On the other hand, T cell responses tend to be more specific
to the site of modification [48]. In the context of a B cell response in MS, it is important to recognise
that MBP has been modified at many sites [9].
Another hypothesis is that the modified MBP could act as a trigger of the innate immune response
by binding to pattern recognition receptors and/or damage-associated molecular pattern receptors to
drive inflammatory processes and lower activation thresholds of T and B cells.
12. A New Theory for MS
It is a corollary that if the extensive modification of MBP in the CNS, coupled with its drainage
into the periphery and the consequent induction of an immune response, (as illustrated in Figure 4),
is validated, it changes the way in which MS is viewed. For example, it renders largely unnecessary a
widely held hypothesis for the induction of MS, based on the sensitisation of autoreactive T cells by
non-CNS antigens derived from the periphery (e.g., molecular mimicry). In the hypothesis outlined in
this article, MS is triggered primarily by the formation of a novel endogenous antigen rather than by
the body’s altered response to an existing antigen.
13. Conclusions
With regard to the consequences, perhaps the most important for MS is that the existence of
MS-specific sites on a major myelin protein opens up the possibility of targeted drug design to prevent,
or treat, MS. Although it is not yet clear why MS presents in several forms, if MS does result from an
immune response to particular modified sites on MBP, then compounds that specifically recognise and
mask these sites could potentially offer a degree of protection. This may be the dawn of a new era in
the treatment of MS.
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